Stephen Barclay

Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study Background and Aims Alcohol-related liver disease (ALD) is a major cause of mortality and disability-adjusted life years. It is not fully understood why a small proportion of patients develop progre...

First first author article for Eemeli Puhakka published!

We identified a profile of metabolites separating those with early stage progressive alcohol-related liver disease from non-progressive alcohol-related liver disease using metabolomics

doi.org/10.1111/liv....

#metabolomics #alcohol

The main benefit of ALBI is better defining prognosis amongst compensated CPT-A patients - if needing albumin then I'd say probably not the score to use.

A close up of a viral of thiamine hanging as a Christmas tree bauble

A Christmas tree upon which there are many vials of thiamine hanging as baubles

Merry Christmas to all on #liversky

Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality - PubMed Primary care pathways for suspected liver disease are increasingly common and often lead to increased specialist hepatology referrals for fibrosis assessment. This study, using clinical follow-up for ...

>13.0 😲
High risk of 90 day decompensation and 12 month mortality - pubmed.ncbi.nlm.nih.gov/38826498/

Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe - PubMed Sub-Saharan African ethnicity has been associated with a higher risk of hepatocellular carcinoma among individuals with chronic hepatitis B. In this international multicenter cohort study of sub-Sahar...

Emails this evening between colleagues in Scotland about HCC surveillance in HBV patients from Sub-Saharan Africa, many performing surveillance at a young age but questioning need (if no advanced fibrosis) in light of pubmed.ncbi.nlm.nih.gov/37898348/ what are others doing? #liversky #hepsky

New people added to the PSC Starter Pack
go.bsky.app/6hLJsJT

Help PSC researchers to connect. Who should be added?

‘At 31, I was told if I didn’t stop drinking, I could die’ BBC journalist Hazel Martin was told she had liver fibrosis and must go teetotal or she could die.

www.bbc.com/news/article...

Nice to see Debbie Shawcross (not on here yet!), @drgautammehta.bsky.social and others really highlighting this issue on various BBC platforms today!

#LiverSky
@adhanda.bsky.social
@aleksanderkrag.bsky.social

Very excited to be on @bbcnews-uk-rss.bsky.social Panorama tomorrow, talking about the hidden harms of binge drinking @stsucl.bsky.social #alcohol #livertwitter #PublicHealth

Add me please Phillipa #NoHep

Pleased to see the publication of our paper showing effective management of alcohol withdrawal syndrome in patients with coexistent alcohol-related liver disease using GMAWS.
Great contributions by our medical students: Stroma Harcombe, Lujine Ibrahim, Georgia Smith and Alex Doyle.
t.co/fEjeZChSVI

Stunning!

Share your best blue sky photo from your phone

Yes!
And low qHBsAg patients are not the majority in our clinics… many left behind

Reflecting on the raft of early phase HBV trials at #TLM24. Good to see new compounds with different MOAs moving forward- however so many of the inclusion criteria were for subjects with low qHBsAg who would have a good chance of S loss with just stopping their NA 🤷🏻‍♂️ #liversky

Lismore lighthouse, off the west coast of Scotland

Excellent study: the 40mg prednisolone for 28 days has been ripe for challenging for a long time now. Dose and duration established only by historical quirk rather than evidence. Need to assess targeted (I would argue NLR rather than severity based) tapered/short duration treatment.
#liversky

Management of primary sclerosing cholangitis: Current... : Hepatology Communications and colorectal cancer. Medical therapies are lacking, and this, in part, reflects a poor grasp of disease biology. As a result, current management is largely supportive, with liver transplantation an ...

The best review on PSC that I have read

journals.lww.com/hepcomm/full...

🫡 @autoimmuneliver.bsky.social
#medsky #liversky

Great to see real world data for GLP1 agonists in MASLD/MASh from the TARGET-NASH Cohort. 10% of cohort received > 1 year. Non users 1.69 RR of decompensation and 2.38 RR all cause mortality #liversky #tlm24

Just updated

Keep it coming

Here! But haven't quite got into the blue sky habit yet!

Glad to be on #medsky - any refugees from #livertwitter made it across yet?